You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 52 Next »

Project Scope 

This project team will define best practices for ensuring that similar types of adverse events are considered together for purposes of safety analyses. This project will develop efficient standardised processes and analyses that can leverage new technologies.

Project LeadsEmails
Mac Gordon (Janssen Research & Development)

rgordon2@its.jnj.com

Peg Fletcher (MedAssessment)peg.fletcher@medassessment.com
Objectives & Deliverables Timelines
Complete White Paper final draft Q2 2023

CURRENT STATUS Q2 2023

Continuing work on a White Paper
Project Members Organisation 
Ashik Chowdhury Cytel 
Barbara HendricksonAbbVie 
Brian Panik MedAssessment 
Charles BeasleyIndependent 
Clio WuChinook Therapeutics
Daniel Wong Genentech 
Emily GorenSeagen 
Gayathri Mahadevan Astrazeneca
Greg Ball ASAPprocess
Jacob RotmenschGenentech 
Jonathan Haddad GSK
Jyoti Agarwal Gilead
Hannah Palac AbbVie 
Harini KunduruDaiichi Sankyo
Heather Robinson Bioxcel Therapeutics
Karen WadeRhoworld
Ketan DurveJanssen Research & Development
Kimberly UmansBiogen
Mary Nilsson Eli Lilly 
Mengchun LiTB Alliance 

Mika Tsujimoto

Eli Lilly 
Nhi Beasley FDA
Pranav Soanker Pfizer 
Radhika M. RaoAbbVie
Ramaiah MuvvalaInductive Quotient
Rebeka Revis IQVIA
Renee Halsing Genentech 
Scott ProestelFDA
Shayami Thanabalasundrum Exelixis
Sunil Kumar ShantharajuBoehringer
Suwen LiRoche
Vaishali PopatFDA
Ying (Heather) HaoProthena 
  • No labels